Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Antipsychotic treatment resistance in schizophrenia remains a major issue in psychiatry. Nearly 30% of patients with schizophrenia do not respond to antipsychotic treatment, yet the underlying neurobiological causes are unknown. All effective antipsychotic medications are thought to achieve their ef...
Main Authors: | Davide Amato, Anna Kruyer, Anne-Noël Samaha, Andreas Heinz |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00314/full |
Similar Items
-
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
by: Sebastiano Alfio Torrisi, et al.
Published: (2020-11-01) -
Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia
by: Jean Claude Martel, et al.
Published: (2020-07-01) -
Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
by: Giuseppe Caruso, et al.
Published: (2020-12-01) -
Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
by: Antonio Rampino, et al.
Published: (2019-01-01) -
Current Concepts and Treatments of Schizophrenia
by: Piotr Stępnicki, et al.
Published: (2018-08-01)